SAN FRANCISCO, June 24 - As genomics struggles through biotech's recent hardships, "drug development" is quickly emerging as the most-favorable business for companies originally built for selling tools and technologies.
...and receive Daily News bulletins.
Already have an account?Login Now.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.